Need professional-grade analysis? Visit stockanalysis.com
$13.87B
N/A
1,189
N/A
Price Chart
Risk-Adjusted Performance
Ascendis Pharma AS (ASND) Price Performance
Ascendis Pharma AS (ASND) trades on United States in USD. The company is classified in the Healthcare sector under the Biotechnology industry. The stock currently trades at $215.54, down 2.86% from the previous close.
Over the past year, ASND has traded between a low of $137.41 and a high of $242.09. The stock has gained 36.2% over this period. It is currently 11.0% below its 52-week high.
Ascendis Pharma AS has a market capitalization of $13.87B.
About Ascendis Pharma AS
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.
Company Info
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- United States
- Currency
- USD
- Country
- United States
Financial Metrics
- Revenue (TTM)
- $720.13M
- EBITDA
- $-131,415,000
- Profit Margin
- -31.67%
- EPS (TTM)
- -4.34
- Book Value
- -3.04
Technical Indicators
- 52 Week High
- $248.58
- 52 Week Low
- $124.06
- 50 Day MA
- $224.33
- 200 Day MA
- $200.61
- Beta
- 0.48
Valuation
- Trailing P/E
- N/A
- Forward P/E
- 43.10
- Price/Sales
- 19.27
- Price/Book
- 14.55
- Enterprise Value
- $14.17B